Quote:

---

If LL is approved in oncology because it was studied with Keytruda then the indication, label and subsequent guidelines will likely reflect how it was studied- ie with Keytruda.

---

Which would make no difference to Merck because it would not affect the expiration of Keytruda's patent. But if they were smart and realized leronlimab has the same type of effect as Keytruda and so much more they may sit up and take notice. I wouldn't count on it though, pharma companies seem hell bent on blowing money on subpar drugs.